(E/Z) -DMU2105

• Description :

  (E/Z) -DMU2105 (Compound 7k) is a potent and highly selective CYP1B1 inhibitor. (E/Z) -DMU2105 inhibits human CYP1B1 enzyme bound to yeast-derived microsomes with an IC50 value of 10 nM. (E/Z) -DMU2105 also potently inhibits CYP1B1 expressed within ‘live’ recombinant yeast and human HEK293 kidney cells with an IC50 value of 63.65 nM. (E/Z) -DMU2105 can be used for the research of cancer, glaucoma, ischemia and obesity[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H315-H319

• Target :

  Cytochrome P450

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/e-z-dmu2105.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CC=CN=C1)/C=C/C2=CC=C3C=CC=CC3=C2

• Molecular Formula :

  C18H13NO

• Molecular Weight :

  259.30

• Precautions :

  P264-P280-P302+P352-P305+P351+P338-P362+P364

• References & Citations :

  [1]Horley NJ, et al. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines. Eur J Med Chem. 2017 Mar 31;129:159-174.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1031063-36-1]